MG
ORKA

Michael Gelband’s Oruka Therapeutics ORKA Stock Holding History

Michael Gelband’s Portfolio ORKA Stock Details ORKA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$14.1M Buy
148,212
+46,858
+46% +$3.12M 0.09% 211
2026
Q1 		$4.97M Buy
+101,354
New +$3.52M 0.04% 441
2025
Q2 		– Sell
-35,912
Closed -$368K – 2067
2025
Q1 		$368K Buy
+35,912
New +$448K ﹤0.01% 1187

Other funds holding ORKA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Michael Gelband's ORKA Position: Q2 2026 in Review

Michael Gelband increased its Oruka Therapeutics (ORKA) stake by 46% in Q2 2026, buying an estimated $3.12M and bringing the position to 148,212 shares worth $14.1M. The position accounts for 0.09% of the portfolio, ranked #211.

Michael Gelband first reported a position in ORKA in Q1 2025 and has held it in 3 quarters since. 254 funds tracked by Wall St. Rank hold ORKA as of Q2 2026.

  • Michael Gelband held 148,212 shares of Oruka Therapeutics worth $14.1M as of Q2 2026.
  • Michael Gelband bought 46,858 Oruka Therapeutics shares in Q2 2026, an estimated $3.12M.
  • Oruka Therapeutics made up 0.09% of Michael Gelband's portfolio in Q2 2026, its #211 holding.
  • Michael Gelband first reported a position in Oruka Therapeutics in Q1 2025 and has held it in 3 quarters since.
  • 254 funds tracked by Wall St. Rank held Oruka Therapeutics as of Q2 2026.

Based on ExodusPoint Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.